NST-1024

NorthSea Therapeutics B.V. · Phase 2 active Small molecule

At a glance

Generic name	NST-1024
Sponsor	NorthSea Therapeutics B.V.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study of the Efficacy and Safety of NST-1024 Versus Placebo in Subjects With Hypertriglyceridemia (PHASE2)
Open-label Study to Evaluate the Effects of NST-1024 on the PK of Multiple Drugs in Healthy Subjects (PHASE1)
A Phase 1, First Time in Humans Study of NST-1024 (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

NST-1024 CI brief — competitive landscape report
NST-1024 updates RSS · CI watch RSS
NorthSea Therapeutics B.V. portfolio CI